Animal models allow researchers to analyze retinal cellular responses to detachment and reattachment systematically and controlled. At Ace Therapeutics, our talented pharmacology team has successfully developed a hyaluronic acid-induced retinal detachment rodent model to help global clients test the effect of therapeutic agents on promoting reattachment and/or reducing detachment. We are committed to supporting our customers in the development and mechanism exploration of upcoming ophthalmic therapies with the highest quality service.
Retinal detachment (RD) is the separation of the neurosensory retina from the underlying retinal pigment epithelium (RPE), severe enough to cause devastating vision loss. This detachment of photoreceptors is common in age-related macular degeneration (AMD), retinal detachment (RD), diabetic retinopathy, retinopathy of prematurity, and retinitis pigmentosa, but the underlying mechanism remains elusive. Animal models can help us to understand how photoreceptor cells work, leading to new treatments. Among the many experimental animal models of retinal degeneration, the rodent retinal detachment model has been widely used because of its reproducibility and feasibility. This model is used to assess different cell death pathways, genetic manipulations, or neuroprotective agents. They may also reveal other information for understanding other causes of blindness due to retinal defects or damage.
Fig. 1. Time course of retinal detachment. (Matsumoto H, et al., 2013)
Subretinal injection of sodium hyaluronate in rodents is the most common and widely accepted method for retinal detachment model establishment. In Ace Therapeutics' laboratory, our research team successfully establish an ideal rodent retinal detachment model using sodium hyaluronate. This model can result in photoreceptor cell death, allowing customers to better understand the pathophysiology of photoreceptor degeneration.
To meet the needs of different researchers, our talented scientists have developed the following two retinal detachment models. These two models provide our global clients with the opportunity to test therapeutics. They are used to evaluate the impact of potential therapies to reduce retinal detachment damage and improve reattachment surgery.
Ace Therapeutics researchers induce partial retinal detachment by first anesthetizing C57BL/6J mice and Brown Norway rats by intraperitoneal injection, followed by transscleral, subretinal injection of 1% sodium hyaluronate to separate the neurosensory retina from the underlying RPE.
Our investigators performed cryosections on days 3 and 7 after RD induction to assess the persistence of RD produced by this method. In addition, photoreceptor degeneration was assessed by counting the number of apoptotic cells using TdT-dUTP terminal nick end labeling (TUNEL) at day 3 and measuring outer nuclear layer (ONL) thickness at day 7 after RD.
To characterize the success of model building and test the potential efficacy of therapeutic drugs, Ace Therapeutics also provides the following supporting endpoint evaluation services, including but not limited to:
Ace Therapeutics has extensive experience in retinal detachment research. Our researchers will provide you with the highest quality retinal detachment models and customized services with the least resources. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!
References